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Abstract
Background: Cancer-related fatigue is one of the most prevalent, prolonged and distressing side effects of prostate
cancer treatment with androgen deprivation therapy. Preliminary evidence suggests natural therapies such as
nutrition therapy and structured exercise prescription can reduce symptoms of cancer-related fatigue. Men appear
to change their habitual dietary patterns after prostate cancer diagnosis, yet prostate-specific dietary guidelines
provide limited support for managing adverse side effects of treatment. The exercise literature has shown high
intensity interval training can improve various aspects of health that are typically impaired with androgen
deprivation therapy; however exercise at this intensity is yet to be conducted in men with prostate cancer. The
purpose of this study is to examine the effects of nutrition therapy beyond the current healthy eating guidelines
with high intensity interval training for managing cancer-related fatigue in men with prostate cancer treated with
androgen deprivation therapy.
Methods/design: This is a two-arm randomized control trial of 116 men with prostate cancer and survivors treated
with androgen deprivation therapy. Participants will be randomized to either the intervention group i.e. nutrition
therapy and high intensity interval training, or usual care. The intervention group will receive 20 weeks of individualized
nutrition therapy from an Accredited Practising Dietitian, and high intensity interval training (from weeks 12–20 of the
intervention) from an Accredited Exercise Physiologist. The usual care group will maintain their standard treatment
regimen over the 20 weeks. Both groups will undertake primary and secondary outcome testing at baseline, week 8,
12, and 20; testing includes questionnaires of fatigue and quality of life, objective measures of body composition,
muscular strength, cardiorespiratory fitness, biomarkers for disease progression, as well as dietary analysis. The primary
outcomes for this trial are measures of fatigue and quality of life.
Discussion: This study is the first of its kind to determine the efficacy of nutrition therapy above the healthy eating
guidelines and high intensity interval training for alleviating prostate-cancer related fatigue. If successful, nutrition
therapy and high intensity interval training may be proposed as an effective therapy for managing cancer-related
fatigue and improving quality of life in men during and after prostate cancer treatment.
Trial registration: Australian New Zealand Clinical Trials Registry ACTRN12615000512527. Trial registered on the 22/5/
2015.
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Background
Prostate cancer has become the most significant major
malignancy of men, severely impacting disease-specific
morbidity and mortality [1–3]. Advances in treatment of
the disease, particularly through the use of Androgen
Deprivation Therapy (ADT; a primary and mainstay
treatment of prostate cancer), has seen prostate cancer
5-year survival rate increase to 92% [2]. Despite ADT’s
efficacy in disease control, the physiological alterations
resulting from ADT have profound adverse effects, in-
cluding increased fatigue [4, 5], metabolic risk [6–8],
cardiovascular risk [6, 9], change in body composition
(increased fat mass and decreased muscle mass) [10, 11],
and reduced functional capacity [12]; the amalgamation
of these side effects severely reduces quality of life [13–15].
Cancer-related fatigue (CRF) is a distressing, persistent,
subjective sense of physical, emotional and/or cognitive
tiredness or exhaustion related to cancer or cancer treat-
ment that is not proportional to recent activity and inter-
feres with usual functioning [16]. CRF is the most common
adverse effect of ADT, with up to 74% of men treated with
ADT experiencing symptoms of CRF [4]. Incidence of CRF
can be seen as early as 12 weeks after treatment initiation,
and may last for longer than 12 months post-treatment in
men treated with ADT [4, 5, 17]. Given the widespread use
of ADT in managing prostate cancer progression, many
men are living with ADT-related side effects during the
course of treatment, and longer into prostate cancer
survivorship. Current management strategies of CRF
are predominantly through pharmacological therapy
[16, 18]; yet more recently, natural therapies such as
diet and exercise have demonstrated clinically signifi-
cant reductions of CRF symptoms in men with prostate
cancer treated with ADT [19, 20].
The benefits of aerobic exercise (performed at 65–80%
age predicted maximum heart rate [APMHR] three
times per week) and progressive resistance training (8–
12 exercises, 2–4 sets of 8–12 repetitions performed 2–3
times per week) in isolation, or when prescribed to-
gether, are well established for improving CRF in men
with prostate cancer [21–25]. Recently, there has been
particular interest in the use of high intensity interval
training [85–95% peak heart rate (HRpeak) interspersed
with period of active recovery] for improving CRF, body
composition, and quality of life in oncological po-
pulations for managing treatment-related side effects
[26–28]. In colorectal cancer survivors, 12 supervised
high intensity interval training sessions (4x4 min bouts
of cycling at 85–95% HRpeak, interspersed with 3 min of
active recovery at 50–70% HRpeak) performed over 4
weeks showed greater improvements in cardiorespira-
tory fitness and total body mass, when compared to 12
supervised moderate intensity exercise sessions (50 min
of cycling at 50-70% HRpeak) [29]. Thus, high intensity
interval training may provide an optimal exercise prescrip-
tion for improving various aspects of health that are typic-
ally impaired with ADT; however exercise at this intensity
is yet to be conducted in men with prostate cancer.
Combined nutrition therapy and exercise prescription
has the potential to optimize management for CRF and
other ADT related side effects. Aerobic exercise (55–
80% APMHR) performed 2-3 times per week for 12-
weeks, with healthy eating group based seminars every 2
weeks, has demonstrated clinically significant improve-
ments in CRF and quality of life in sedentary men
treated with ADT [19, 20]. In contrast individual nutrition
advice to meet the United Kingdom Dietary guidelines
[30] with 30 min per day of brisk walking for 24 weeks
demonstrated no significant changes in CRF or quality of
life compared to usual care [31]. Thus it appears CRF may
be better managed with structured exercise prescription
and concurrent healthy eating. Whilst Bourke and col-
leagues [19, 20] demonstrated significant improvements in
CRF, the nutrition consults were group-based, which fails
to consider individual dietary requirements and is not rep-
resentative of standard dietetic practice. Thus the effects
of tailored nutrition therapy beyond the healthy eating
guidelines, with adjunctive structured exercise prescrip-
tion on the burden of CRF remains to be elucidated.
Dietary manipulation has been identified to be an
important lifestyle factor to alleviate ADT related side
effects [32–34]; yet the efficacy of dietary interventions
in isolation during treatment or into prostate cancer
survivorship are limited for supporting the adverse side
effects seen from ADT. Importantly, prostate cancer-
specific dietary guidelines provide limited support and
guidance for alleviating adverse treatment-related side
effects, including CRF [35, 36]. In non-oncological popu-
lations, structured individualized nutrition therapy by an
Accredited Practising Dietitian is recommended for
adults who are overweight, obese, insulin resistant, and
have altered lipid and triglyceride metabolism [37–39];
all notable adverse side effects from ADT. Yet the transla-
tion of this nutrition therapy in prostate cancer is yet to
be elucidated. Recently, a Mediterranean-style diet pattern
has been shown to improve metabolic and cardiovascular
parameters in men at risk of prostate cancer [40]. Adher-
ence to an anti-inflammatory properties of a Mediterra-
nean diet have shown small reductions in hypertension
(reduced systolic blood pressure; SE = – 1.44mm Hg
[95% CI, -2.88 – 0.01]; and diastolic blood pressure;
SE = -0.70mm Hg [95% CI, -1.34 – 0.07) [41], and risk
of type 2 diabetes (RR = 0.93; 95% CI, 0.89 – 0.98)
[42]; thus showing plausible metabolic and cardiovas-
cular effects on known ADT related side effects. Yet
practical application of the Mediterranean-style diet pat-
tern to men treated with ADT for management of CRF
and improving quality of life is yet to be ellucidated.
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Literature to date has encompassed general healthy
eating guidelines for the management of prostate cancer
treated related side effects [19, 20, 31], however general
guidelines do not take into account the specific dietary
requirements needed to manage the ADT-related side
effects. Therefore, the role of specific individualized
nutrition therapy tailored to alleviate the side effects
of ADT, particularly CRF, and improve quality of life
warrants investigation.
This study aims to:
1. Investigate whether 12-weeks of nutrition therapy,
compared to 12 weeks of usual care, can improve
prostate CRF and quality of life in men treated
with ADT.
2. Assess the combined benefits of 20-weeks of
nutrition therapy with 8-weeks of high intensity
exercise (weeks 12–20), compared to 20 weeks
of usual care, on CRF and quality of life in men
treated with ADT.
We hypothesized that 12-weeks of nutrition therapy,
compared to 12 weeks of usual care, will improve CRF
and quality of life in men with prostate cancer treated
with ADT. It is further hypothesized a 20-week nutrition
therapy intervention with 8 weeks of high intensity
interval training, compared to 20 weeks of usual care,
will improve CRF and quality of life in men with pros-
tate cancer treated with ADT. Secondary measures of
body composition, functional capacity, metabolic syn-
drome and biomarkers such as prostate specific antigen,
insulin like growth factor [43]-1, IGF-2, IGF binding
protein-3, interleukin [IL]-6, and IL-8), will be measured
and analyzed between and within groups. We hypothesis
nutrition therapy alone, and with high intensity exercise
will improve body composition, functional capacity, and
biomarkers of metabolic syndrome and prostate cancer
progression.
Methods/design
The study is a two-arm randomized controlled trial
design conducted at The University of Queensland
School of Human Movement and Nutrition Sciences.
All primary and secondary outcomes will be measured
at baseline, week 8, 12, and 20. A total of 116 men
with prostate cancer treated with ADT (>3 months)
will be randomized to either a 20-week nutrition ther-
apy with 8 weeks of high intensity exercise (per-
formed from weeks 12 to 20) or a control group of
usual care. A person independent to the study will
conceal participant allocation, after baseline testing
using a random number generator into either group,
with equal probability. The study will be guided by
the CONSORT statement [44] (Fig. 1).
Participant eligibility
To be eligible to participate in this study, men must
meet the following inclusion criteria: (a) aged ≥18 years,
(b) non-smoker, or have quit smoking for ≥3 months, (c)
a diagnosis of prostate cancer, and have been under-
taking ADT for ≥3 months, (d) body mass index of
18.5-34.9 kg/m2 (i.e. normal weight, overweight or obese
class I). Exclusion criteria include: (a) taking any supple-
ments other than a single multivitamin, unless stated for
medical purposes, (b) have any musculoskeletal, neuro-
logical, respiratory, metabolic or cardiovascular conditions
that may prevent safe completion of the exercise demands
of the study, as determined by a Urologist, (c) current in-
fection, (d) bone metastases, (e) currently undertaking
high intensity exercise i.e. ≥90% heart rate max (HRmax)
or ≥7 rating of perceived exertion (RPE; Borg’s rating of
perceived exertion scale, category scale 0-10).
Recruitment and informed consent
Participants will be recruited from the Mater Adults
Hospital, Brisbane, Australia; The University of Queens-
land, Australia; and the Cancer Council Queensland,
Australia. Participants will also be recruited by way of
media releases, presentations and advertisements in
newsletters, newspapers, and noticeboards at The Uni-
versity of Queensland, Cancer Council Queensland, and
the Prostate Cancer Foundation of Australia support
groups. All participants will be complete a brief te-
lephone screening questionnaire to verify eligibility.
Eligible participants will be asked to seek guidance from
their Urologist regarding participation in the study, and
sign the consent form prior to participating in the study.
Approval of the trial protocol was obtained from the
Mater Research Ethics Committee (HREC/15/MHS/38)
and The University of Queensland Human Research
Ethics Committee (2015001245) prior to recruitment.
Randomisation
After baseline testing, participants will be randomly allo-
cated to either the nutrition therapy with high intensity
exercise or the standard care group using a 1:1 ratio.
The randomisation process will be conducted by a com-
puterized system using a random number generator,
with equal probability, by a person external to the study.
Measurements
All measurements for primary and secondary outcomes
will take place at baseline, week 8, week 12, and week 20
(see Table 1). A familiarization trial including the func-
tional capacity and peak aerobic power (V̇O2peak) tests
will take place at least 7 days prior to baseline testing.
Participants will be asked to refrain from vigorous exer-
cise, caffeine, alcohol, food and beverages (except for
water) for 12 h before all testing sessions.
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Primary outcomes
Fatigue
Fatigue will be measured using The Functional Assess-
ment of Cancer Therapy: Fatigue (FACT-F) question-
naire, which reports weekly fatigue on a scale of 0–52,
with higher values indicating less fatigue [45]. The
FACT-F has shown good reliability and validity (Cron-
bach’s α: 0.93-0.94) for predicting clinically significant
treatment outcomes of CRF [46].
Cancer-specific quality of life
The European Organization for Research and Treatment
of Cancer (EORTC) QLQ-C30 is a 30 item cancer-
specific instrument including the following domains;
physical, role, emotional, social, and cognitive, global
quality of life, fatigue, pain, and emesis. The EORTC
QLQ-C30 has shown a high reliability (Cronbach’s α;
0.63-.80) in cancer patients [47].
Prostate cancer-specific quality of life
The EORTC QLQ–PR25 is a 25 question prostate
cancer-specific instrument including domains; urinary,
bowel, use of incontinence aids, treatment-related symp-
toms, sexual activity and sexual function [48]. The
EORTC QLQ – PR25 questionnaire has shown good in-
ternal reliability (Cronbach’s α; 0.70-0.86) for prostate
specific treatment-related side effects [49].
General health and well-being
The Medical Outcomes Study 36-Item Short-Form 36
Health Survey (SF-36) is scored by eight scales
encompassing physical and mental measures [50].
The SF-36 questionnaire has widely been used to
measure general health and well-being, with good
construct validity (Cronbach’s α; > 0.85) in cancer
patients [51].
Fig. 1 CONSORT diagram and schematic representation of the study. Legend: Wk = week, HIIT = high intensity interval training
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Secondary outcomes
Physique traits and body composition
Height, body mass, and waist circumferences will be mea-
sured according to the International Society for the Ad-
vancement of Kinathropometry (ISAK) procedures [52].
Body composition (fat mass, lean mass, body fat
percentage and bone mineral density) will be assessed
using dual energy X-ray absorptiometry (DXA; Hologic
Discovery A, Waltham, MA, USA).
Muscular Strength and Power
Isometric strength of dominate and non-dominate hand-
grip will be assessed using a spring-loaded grip
dynamometer (TTM, Tokyo, Japan) to estimate physical
performance [53], and muscular strength [54]. Participants
will perform the test three times on each hand with the
best result used for analysis. Muscular strength of the
chest and legs will be measured using the one repetition
maximum (1RM) chest and leg press methods, respect-
ively [55]. The sit to stand test will be used to assess func-
tional leg power [12]. Participants will perform the test
three times with the best result used for analysis.
Exercise capacity and cardiorespiratory fitness
The six-meter walk test will involve participants walking
a marked 10-m distance as quickly as safely possible,
Table 1 Data collection schedule
Assessments Time (weeks)
Baselinea Week 8 Week 12 Week 20
Screening
Participant eligibility ✓ Randomization
Adult Pre-exercise Screening System ✓
Medical history form and medications ✓
Primary outcomes
Function Assessment of Cancer Therapy-Fatigue ✓ Randomization ✓ ✓ ✓
European Organization of Research and Treatment of Cancer QLQ-C30* ✓ ✓ ✓ ✓
European Organization of Research and Treatment of Cancer QLQ-PR25□ ✓ ✓ ✓ ✓
The Medical Outcomes Study 36-Item Short-Form 36 ✓ ✓ ✓ ✓
Second Outcomes
Anthropometric physique traits ✓ Randomization ✓ ✓ ✓
Body compositionb ✓ ✓ ✓ ✓
Isometric strength ✓ ✓ ✓ ✓
Chest and leg one repetition maximum test ✓ ✓ ✓ ✓
Sit to stand test ✓ ✓ ✓ ✓
Six-meter walk test ✓ ✓ ✓ ✓
400-meter walk test ✓ ✓ ✓ ✓
Cardiorespiratory fitnessc ✓ ✓ ✓ ✓
Blood collection ✓ ✓ ✓ ✓
Wollongong Dietary Inventory ✓ ✓ ✓ ✓
24-h diet recalld ✓ ✓ ✓ ✓
Depression Anxiety Stress Scale ✓ ✓ ✓ ✓
Insomnia Severity Index ✓ ✓ ✓ ✓
Physical Activity Enjoyment Scale ✓ ✓ ✓ ✓
Godin Leisure-Time Physical Activity Questionnaire ✓ ✓ ✓ ✓
Accelerometere,f ✓ ✓ ✓ ✓
aNutrition and exercise intervention commences Week 0 after randomisation
bDual energy X-ray absorptiometry
cV̇O2peak test
dConducted every 2 weeks
eActigraph GT3X+
fto be worn for 7 consecutive days
*Cancer quality of life questionnaire for people with cancer
□Cancer quality of life questionnaire for people with prostate cancer
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with performance timed over the middle 6-m distance to
minimize the influence of acceleration and deceleration
[12]. The 400-m walk test will be used to estimate exer-
cise capacity [12]; participants will be required to walk
10 laps out and back over a 20-m course (400 m total)
as fast as safely possible.
Cardiorespiratory fitness will be assessed using a
V̇O2peak test. The test will involve a modified ramp
protocol described by Wasserman et al [56] on a cycle
ergometer. Participants will begin with 3 min of rest for
respiratory normalization, followed by 4 min of warm-
up at a resistance of 50 Watt. The electrical resistance
provided by the cycle ergometer increases incrementally
by 20-30 W.min-1. Participants will cycle at a cadence
between 60 and 70 revolutions per minute throughout
the test. Heart rate will be continuously recorded
throughout the exercise using a heart rate monitor
(Polar FT1; Polar, Kempele, Finland) and blood pressure
(Durashock Sphygmomanometer; Welch Allyn, New
York, USA) will be recorded every 2 min throughout the
test. At the conclusion of each minute participants will
indicate their rating of perceived exertion (RPE) on the
Borg 6-20 scale [57]. The test will be terminated when
the participant reaches volitional fatigue or at the discre-
tion of the researchers with consideration for exercise
testing termination criteria as outlined by the American
Association of Cardiovascular and Pulmonary Rehabili-
tation [58]. The gas analyzers and ventilometer will be
calibrated prior to and verified after each test. Sampled
expired air will be measured every 15 s using a turbine
ventilometer (Morgan, Model 096, Kent, England). The
ramp V̇O2peak protocol has good validity in comparison
to the standard Bruce protocol [59]. V̇O2peak will be
recorded as the highest V̇O2 reading averaged over two
consecutive readings.
Blood collection and analysis
A trained phlebotomist will extract, treat and subse-
quently store the blood at approximately -80°C until later
analysis. Analysis of blood samples through commercial
ELISA kits (Thermo Fisher Scientific Australia Pty Ltd.,
Victoria, Australia; Randox Laboratories Ltd., West
Virginia, USA; R&D Systems Inc., Minneapolis, USA)
will be used for PSA, IGF-1, IGF-2, IGFBP3, IL-6, IL-8,
Hepcidin, total cholesterol, and triglycerides analysis.
Dietary intake
Participants will complete the Wollongong Dietary Inven-
tory [60] (a comprehensive dietary history of intake over
the past month) with cross-checking quantification from
an Accredited Practising Dietitian. Narrative approaches
to diet histories have been shown to provide good repro-
ducibility and reliability compared to food records [61].
Food models and pictures of food portions (Great Ideas in
Nutrition, Coolangatta, Australia) will be utilized to im-
prove the accuracy of food intake estimates [62].
Other measures
Psychosocial: Depression Anxiety Stress Scale (DASS)
The DASS is a 42-item self-report instrument design to
measure the three related negative emotional states of
depression, anxiety, and stress [63], and has been vali-
dated for measuring emotional states of depression
(Cronbach’s α: 0.94), anxiety (Cronbach’s α: 0.88) and
stress (Cronbach’s α: 0.93) in clinical populations [64].
Insomnia Severity Index (ISI)
The ISI questions relate to subjective qualities of the
respondents sleep, including satisfaction with sleep
patterns, the degree to which insomnia interferes with
daily functioning, and how the respondent feels their
insomnia is noticeable to others [65]. The ISI has
shown excellent internal consistency (Cronbach’s α:
0.90) for detecting symptoms of insomnia.
Physical activity enjoyment scale (PACES)
The physical activity enjoyment scale (PACES) will be used
to assess participant enjoyment of the high intensity inter-
val exercise PACES consists of 17 subscales that each relate
to an aspect of enjoyment; along a 7-point continuum for
each subscale, participants are asked to provide a rating to
reflect their agreement with one of two bi-polar statements
(e.g. ‘I enjoy it’ – ‘I hate it’) [66]. The PACES questionnaire
has shown high internal consistency (Cronbach’s α: 0.90) in
measures of exercise enjoyment [67].
Godin leisure-time physical activity questionnaire
The Godin leisure-time physical activity questionnaire
requires participants to recall during a typical 7-day
week the frequency and duration of exercise completed
at three separate intensities: mild, moderate, and strenu-
ous intensity [68]. The Godin leisure-time physical activ-
ity questionnaire has shown high agreement and
validation (agreement: 70.8%) with minutes spent phys-
ically active, in comparison to an accelerometer in breast
cancer survivors [69].
Accelerometer
Participants will be asked to maintain their current level
of physical activity outside of the testing sessions for the
duration of the study. Physical activity will be objectively
assessed using the Actigraph GT3X+ accelerometer
(Actigraph, Pensacola, Florida), a small, waist-worn,
non-invasive device. Few studies have been published on
the validity of the GT3X+ version of the Actigraph
accelerometer specifically, however previous versions
of the Actigraph accelerometer (CSA and GT1M)
have demonstrated waist-worn validity in treadmill
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walking and running compared with indirect calorim-
etry (r = 0.56, p < 0.001 and r = 0.53, p < 0.05, respect-
ively) in adults [70, 71].
Interventions
Nutrition therapy with high intensity exercise
Detailed diet histories will be conducted at baseline week
8, 12 and 20 using the Wollongong Dietary Inventory
[60], and 24 h diet recalls every two weeks during the
intervention. Each consult will take approximately 30-45
min and involves an Accredited Practising Dietitian ask-
ing detailed questions about the foods consumed and
the amount and frequency of consumption. The 20-
week diet emphasizes a total energy intake decrement
using the Harris-Benedict predicted energy requirements
[72]; with a dietary composition of 45-65% carbohydrate,
20-35% fat, saturated fat <10% total energy intake, and
15-25% protein sources. Dietary advice will be tailored
according to current body composition classification as
‘normal, overweight or obese stage I’ (see Fig. 2). A diet-
ary energy reduction of 2000-4000 kJ/day will be empha-
sized at baseline consultation if body composition and
diet intake are classified average or poor according to
Fig. 2: Nutrition therapy schematic representation. The
diet intervention will encompass a Mediterranean-style
diet containing cruciferous vegetables (broccoli, bok
choy, cauliflower) [73], tomato and tomato-paste con-
taining products (lycopene) [74, 75], fruits, calcium and
vitamin D containing foods, polyunsaturated, monoun-
saturated, omega 3 and 6 fatty acids (<10–15% total en-
ergy intake) [76], and a reduced consumption of red
meat (<2 a week) [77, 78]; as seen in Table 2: Nutrition
recommendations. Each individual nutritional consult-
ation, will aim to make gradual changes to the partici-
pants’ diets to best achieve a modified Mediterranean-
style dietary pattern. Standard dietetics practice will be
used to assess and providing guidance on managing the
nutritional impact symptoms from treatment (including
broader intolerances/allergies).
Each participant in the intervention group will be
provided with a nutrition pamphlet for supportive
education during the study to represent standard dietetic
practice. The nutrition pamphlet will be provided at the
first dietetic consult and is designed to facilitate the diet-
etic consultation to help maintain a Mediterranean-style
diet pattern. The pamphlet consists of background in-
formation about nutrition requirements, optimal nutri-
tion during prostate cancer based on current evidence
Fig. 2 Nutrition therapy assessment schematic representation. Legend: DEXA = Dual-energy X-ray absorptiometry, F = fruit, V = vegetable, Sat
fat = saturated fat, EER = estimated energy requirement, HIIT = high intensity interval training, Std = standard drink, BMI = body mass index
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(kilojoule/cal, fatty acids, carbohydrate, meats and
protein, fruits and vegetables, cruciferous vegetables,
lycopene, soy isoflavones, vitamin C and calcium, alcohol
and discretionary foods) and exercise during prostate
cancer treatment. The pamphlet further consists of
Decision Balance Tools to help change dietary patterns
if needed throughout the dietetic consults by identifying
possible barriers to adopting the nutrition therapy.
These form part of standard dietetics practice involving
motivational interviewing.
Baseline body composition scans (DXA) will classify
participants as normal, overweight, or obese state I,
according to age specific normative Z values for percent-
age of body mass index and fat mass [79]. The current
diet will be quantified into food groups, total energy
intake, and saturated fat intake. From this the diet will
be classified as ‘generally healthy’, ‘average’ or ‘poor’ com-
pared to the Australian Dietary Guidelines [80] (as seen
in Fig. 2: Nutrition therapy schematic representation).
To improve adherence, the nutrition therapy will not be
prescriptive, and instead utilize individualized food-
based goals with the aim to progressively increase the in-
take of plant-based foods over the duration of the inter-
vention to meet a modified Mediterranean-style diet
pattern.
From weeks 12–20 participants will be required to
visit The University of Queensland’s School of Human
Movement and Nutrition Sciences three times per week
to complete high intensity interval training sessions.
Prior to exercising, participants’ heart rate and blood
pressure will be measured for contraindications to
commence exercising as outlined by the American
College of Sports Medicine [81]. The high intensity exer-
cise sessions will commence with 10 min of warm up at
50–70% HRpeak before completing 4 x 4 min bouts of
cycling at 85–95% HRpeak. Each 4 min interval will be
interspersed with a 3 min period of active recovery at
50–70% HRpeak, totaling 38 min for the session. The
high intensity exercise sessions will be conducted on an
air- and magnetically-braked cycle ergometer (Wattbike
Table 2 Nutrition recommendations
Food/Nutrient Serving summary Recommendation
Total Energy Intake As specified by your Accredited Practising Dietitian,
using the Harris-Benedict equation.
Within requirements
Saturated fat 1 serve = 1 tablespoon of butter, 1 sweet biscuit.
Excess fat on meat, full-cream dairy, take-away
foods, cakes, bakery items, processed meats,
vegetable oil.
<10% total energy
Refined Carbohydrates Serving size = 1 (40g) Donut, 30g potato chips,
12 hot chips, 1 can of soft drink (375ml), ½
small chocolate bar (25g)
Limit consumption
Whole Grains 1 serve = 1 slice of multigrain bread, ½ cup oats, 4-6 serves per day
Fruits and Vegetables One serving = 1 medium piece (apple, banana,
orange, pear), 2 small pieces (e.g. apricot, kiwifruit,
plums), ½ cup of tomato, ½ cup or carrot, ½ cup
green beans, ½ cup of pumpkin, 100g mixed
frozen vegetables
2 fruits and 5 vegetables per day
Fibre Aim for 30g/day through your grains, vegetables,
and fruit intake
30g/day through grains, fruits
and vegetable intake
Lentils/Beans 1 cup per day of cooked or canned legumes/beans
such as lentil, chick peas or split peas
1 cup per day
Lean Meats Lean meats 3-4 times per week. Serving size of 65g
include beef, lamb, veal, port, and 80g for chicken,
turkey, duck, and 2 large eggs
Lean meats 3-4 times per week
Meats with carcinogenic properties Red charred meat, visible from over cooking
or burning the mean. Processed meats
(i.e. salami, sausage)
Reduce or eliminate
Oily Fish 100g per serve of fresh salmon, tuna, trout 2-3 times per week
Dairy 1 cup of fresh, reduced fat milk, or soy milk 2-3 serves per day
Nuts and Seeds 30g (handful) of almonds, cashew nuts, walnuts,
macadamia nuts, brazil nuts, pumpkin seed,
sunflower seeds
30g per day
Alcohol and discretionary foods 1 standard drink of alcohol = 375ml mid strength
beer, 1 glass of wine, 30ml spirit. Discretionary
foods = biscuits
0-2 standard serves of alcohol, and
reduce or eliminate discretionary foods.
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Ltd., Nottingham, England). Participants will continue to
receive the same dietetic intervention outlined above
from weeks 12–20.
Usual Care
Participants randomized to usual care will continue their
usual medical care during this period. Participants in the
usual care group will be monitored for 20 weeks and
perform identical primary and secondary outcome mea-
sures at the same time points as outlined above for the
intervention group.
Sample Size Calculation
Sample size calculations were complete using Vanderbilt
Power and Sample Size software (Vanderbilt University,
TN). Combined diet and exercise interventions with
CRF as an outcome are relatively limited. A diet and ex-
ercise intervention in men treated with ADT showed
prostate cancer-specific CRF (as measured by FACT-F)
scores improved by 3.7 – 14.2 (CI, 95%; adjusted mean
8.9 points) in the intervention group compared to the
control group [20]. Assuming FACT-F scores for this
group were normally distributed with a SD of 8.9, a true
difference between the experimental and control arms of
5.2, and a power of 0.8, we would need 47 experimental
and control participants to be able to reject the null
hypothesis. The type 1 error probability associated with
this test of the null hypothesis is 0.05. With an antici-
pated 20% attrition rate based on previous research from
our laboratory, we would need 58 experimental and
control group participants to be able to reject the null
hypothesis.
Statistical Analysis
Data will be analyzed using the SPSS statistical software
package (version 20.0, SPSS, Inc., Chicago, IL). Normality
of the distribution for all outcome measures will be
assessed using the Kolmogorov Smirnov test. Analyses will
include standard descriptive statistics, t tests, correlation,
regression and two-way repeated measures ANOVA or
the comparable non-parametric test as necessary to exam-
ine differences between and within groups, at baseline and
weeks 8, 12, and 20.
Data Collection, Management and Monitoring
The principle investigator and trained research assistants
will collect anthropometric, diet, exercise and lifestyle
data from the study participants. Inter- and intra-tester
reliability will be determined for data collecting investi-
gators and research assistants for all outcome measures
as appropriate. Computer files containing study data will
be de-identified and password protected with access only
available to study investigators. All research notes and
data will be kept in a securely locked filing cabinet at
The University of Queensland School of Human Move-
ment and Nutrition Sciences. The investigators will
comply with the Good Clinical Practice (GCP) guidelines
adopted by the Therapeutic Goods Administration and
document all adverse events through the Human Re-
search Ethics Committee (HREC). The study investiga-
tors will permit study-related monitoring, audits, and
inspections by Mater HREC of all study related docu-
ments (e.g. source documents, regulatory documents,
data collection instruments, study data) and study
facilities (e.g. diagnostic laboratory). This study will be
conducted in full conformance with the principles of the
‘Declaration of Helsinki’ according to international
standards of GCP guidelines, applicable Australian gov-
ernment regulations and Institutional research policies
and procedures.
Discussion
CRF is a distressing and prolonged symptom associated
with prostate cancer treatment. Management of CRF is
critical for improving quality of life during and after
treatment for prostate cancer [4, 5, 82]. Nutrition ther-
apy and exercise prescription have the potential to
improve CRF and other prostate cancer disease- and
treatment-related side effects [19–21, 25, 83–85]. This
clinical trial is the first to investigate the efficacy of
nutrition therapy above the healthy eating guidelines in
managing prostate CRF. The lack of dietary guidelines
for men with prostate cancer is a limitation in the
current treatment and management of prostate cancer;
thus investigating individual structured nutrition therapy
provides novel insight to the efficacy of dietary modifica-
tion in managing CRF and other side effects from ADT.
This project will expand the exercise oncology literature
by investigating the efficacy of high intensity interval
training for reducing CRF and improving quality of life
in men with prostate cancer. Considering both individ-
ual nutrition therapy beyond general healthy eating
guidelines and high intensity interval training are yet to
be investigated in men with prostate cancer, this land-
mark study will provide novel evidence to support the
development of guidelines to optimise the management
of CRF and other side effects from ADT. It is hypo-
thesized that nutrition therapy alone, and with high
intensity interval training will improve CRF and
ADT-related side effects.
Dissemination of the results from this study to oncolo-
gists, urologists, prostate cancer nurses, dietitians, nu-
tritionists, exercise physiologists and other exercise
specialists will be important to ensure an evidence-based
approach to the use of nutrition and exercise in the
management of prostate CRF. Currently CRF is managed
primarily with medications. Natural therapies such as
diet and exercise provide a multi-faceted approach to
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managing CRF, which may in turn improve other associ-
ated side effects seen from ADT (e.g. metabolic and
cardiovascular risk). With the rising incidence of pros-
tate cancer and increasing survival rates, the primary
outcome from this study will be to provide evidence to
enhance clinical practice in nutrition, diet and exercise
therapy to improve the lives of men suffering from the
disease- and treatment-related side effects of prostate
cancer.
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